Skip to content
Screener

SG&A at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$6.43B+9.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$662.1M+4.4%
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
$22.75M-4.7%
AbbVie logo
AbbVieABBV
$3.63B+11.7%
Bausch + Lomb logo
Bausch + LombBLCO
$588M+1.6%
HRO
HarrowHROW
$43.23M+6.7%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.09B+98.7%
Enterprise value$10.08B+98.3%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Cost of sales34,01626,89667,35551,212
Gross profit151,59497,224268,826179,572
Operating expenses:
Selling, general and administrative116,06083,375209,003154,048
Research and development51,30136,53895,44668,891
Acquired in-process research and development1,500-1,500-
Total operating expenses168,861119,913305,949222,939
Loss from operations(17,267)(22,689)(37,123)(43,367)

Item 1. Financial Statements

FAQ

What is Glaukos's SG&A?
Glaukos (GKOS) reported SG&A of $116.06M in Q2 2026.
How has Glaukos's SG&A changed year-over-year?
Glaukos's SG&A increased by 39.2% year-over-year, from $83.38M to $116.06M.
What is the long-term trend for Glaukos's SG&A?
Over 4 years (2021 to 2025), Glaukos's SG&A has grown at a 16.6% compound annual growth rate (CAGR), from $179.26M to $331.75M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Ask your AI about Glaukos's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude